Cannabinol for Sleep and Insomnia: A Critical Narrative Review and an Olive-Derived Polyphenol Combination Hypothesis
- 1Department of Physical Education and Sport Science, University of Thessaly, 42100 Thessaly, Greece
- 2Laboratory of Pharmacognosy and Chemistry of Natural Products, Department of Pharmacy, National and Kapodistrian University of Athens, Panepistimioupoli Zografou, 15771 Athens, Greece
- 3Department of Life Sciences, School of Life and Health Sciences, University of Nicosia, 2417 Nicosia, Cyprus
Abstract
Cannabinol (CBN) is marketed for sleep, but its clinical evidence is limited and heterogeneous. This critical narrative review evaluates CBN-specific sleep studies and considers an olive-derived phenolic combination as a separate, untested clinical hypothesis. Three key randomized trials enrolled different populations and used oral doses of 20–300 mg over one night to four weeks. Primary sleep-quality or sleep-maintenance outcomes were not consistently positive; dose-ranging signals were multiplicity-sensitive and did not identify an optimal dose. At 300 mg, an acute insomnia trial reported selected secondary sleep benefits alongside next-day vigilance and simulated-driving concerns. Rodent findings implicate CBN and its metabolites, but route, exposure, tolerance and dependence limit extrapolation. Oleocanthal studies measured behavioral sleep in disease-model mice, whereas a human olive-phenol trial reported a fatigue benefit rather than a separately demonstrated sleep-domain effect. Parent phenolic instability, metabolism and uncertain target-site exposure weaken direct translation of micromolar assays. The proposed combination warrants exposure-informed investigation, not therapeutic endorsement. Progress requires product-specific safety and analytical qualification, component-controlled experiments and patient-prioritized outcomes alongside established insomnia care.
Related
- Combination Therapy of Extracorporeal Shock Wave Therapy and Platelet-Rich Plasma for Musculoskeletal Disorders: A Narrative Review.
- Mitophagy and Ferroptosis in Diabetic Kidney Disease: A Hypothesis of Their Synergistic Interplay in Renal Tubular Injury—A Narrative Review
- Safety profiles of current and emerging neoadjuvant immune-modulatory and combination strategies in borderline resectable stage III non-small cell lung cancer: a narrative review
- Diagnostic potential of Aldo-keto reductase 1B10 in pediatric hepatic malignancies: a narrative, hypothesis-generating translational review based on adult evidence and future research directions
- Extraction and spectroscopic characterization of polyphenol- and saponin-rich extracts from musa balbisiana corm with tentative identification of quercetin.
BibTeX
@article{pita2026cannabinol,
title = {{Cannabinol for Sleep and Insomnia: A Critical Narrative Review and an Olive-Derived Polyphenol Combination Hypothesis}},
author = {Dimitra Pita and Prokopis Magiatis and Evangelos Dadiotis and Eleni Melliou and Ilias Ntoumas and Christina Karatzaferi and Giorgos K. Sakkas},
journal = {Nutrients},
year = {2026},
month = nov,
doi = {10.3390/nu18213659},
url = {https://www.mdpi.com/2072-6643/18/21/3659},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Cannabinol for Sleep and Insomnia: A Critical Narrative Review and an Olive-Derived Polyphenol Combination Hypothesis
AU - Dimitra Pita
AU - Prokopis Magiatis
AU - Evangelos Dadiotis
AU - Eleni Melliou
AU - Ilias Ntoumas
AU - Christina Karatzaferi
AU - Giorgos K. Sakkas
PY - 2026
DA - 2026/11/04
JO - Nutrients
DO - 10.3390/nu18213659
UR - https://www.mdpi.com/2072-6643/18/21/3659
AB - Cannabinol (CBN) is marketed for sleep, but its clinical evidence is limited and heterogeneous. This critical narrative review evaluates CBN-specific sleep studies and considers an olive-derived phenolic combination as a separate, untested clinical hypothesis. Three key randomized trials enrolled different populations and used oral doses of 20–300 mg over one night to four weeks. Primary sleep-quality or sleep-maintenance outcomes were not consistently positive; dose-ranging signals were multiplicity-sensitive and did not identify an optimal dose. At 300 mg, an acute insomnia trial reported selected secondary sleep benefits alongside next-day vigilance and simulated-driving concerns. Rodent findings implicate CBN and its metabolites, but route, exposure, tolerance and dependence limit extrapolation. Oleocanthal studies measured behavioral sleep in disease-model mice, whereas a human olive-phenol trial reported a fatigue benefit rather than a separately demonstrated sleep-domain effect. Parent phenolic instability, metabolism and uncertain target-site exposure weaken direct translation of micromolar assays. The proposed combination warrants exposure-informed investigation, not therapeutic endorsement. Progress requires product-specific safety and analytical qualification, component-controlled experiments and patient-prioritized outcomes alongside established insomnia care.
SN - 2072-6643
ER -